IMA
ImageneBio Inc
NASDAQ · Healthcare · Biotechnology · US
$4.85
−0.72%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -28.1%
- EBIT
- -32.6%
- EPS
- -3.4%
- Free cash flow
- -97.8%
- Operating cash flow
- -97.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +25.3%
Three-year CAGR
- Revenue
- -62.9%
- EBITDA
- -27.5%
- EBIT
- -30.9%
- Net income
- -24.0%
- EPS
- +76.2%
- Free cash flow
- -4.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026